Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Stopped Other- Protocol moved to Disapproved
Conditions
- Estrogen Receptor Negative
- Head and Neck Squamous Cell Carcinoma
- HER2/Neu Negative
- Hormone-Resistant Prostate Cancer
- Metastatic Pancreatic Adenocarcinoma
- Progesterone Receptor Negative
- Solid Neoplasm
- Stage III Mesothelioma
- Stage IIIA Gastric Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Small Cell Lung Carcinoma
- Stage IIIB Gastric Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Small Cell Lung Carcinoma
- Stage IIIC Gastric Cancer
- Stage IIIC Ovarian Cancer
- Stage IV Mesothelioma
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Ovarian Cancer
- Stage IV Small Cell Lung Carcinoma
- Triple-Negative Breast Carcinoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- OTHER: Pharmacological Study
- DRUG: Talazoparib
Sponsor
National Cancer Institute (NCI)